1.1 Controls
for the Prevention And Detection Of Fraudulent Or Abusive Practices
The contractor shall establish
procedures and utilize controls for the prevention and detection
of fraudulent or abusive patterns and trends in billings by providers,
pharmacies, entities, and beneficiaries on a pre- and postpayment
basis. Controls shall include the following (and be made available
to the Defense Health Agency (DHA) Program Integrity Office (PI)):
• Eligibility verifications for
beneficiaries and providers/pharmacies.
• Coordination of benefits.
• Prepayment edits (e.g., applied
to program exclusions and limitations).
• Utilization of discretionary
or coordinated placement of providers/beneficiaries on prepayment review.
• Postpayment utilization review
to detect fraud and/or abuse by either beneficiaries, pharmacies,
or providers and to establish dollar loss to the Government.
• Application of security measures
to protect against embezzlement or other dishonest acts by employees.
• Incorporate anti-fraud attestation
language whenever/wherever practical (e.g., claim forms, network
agreements, electronic claims submission agreements).
• Utilization of Fraudlines/Hotlines.
• Prepayment duplicate screening.
• Postpayment duplicate screening.
• Verification of provider status
(e.g., credentials, licensure) to include appropriate termination
action when findings/recommendations of boards, etc. results in
loss or suspension of licensure or certification.
• Program Integrity (PI) targeted
measures (e.g., prepay anti-fraud review; use of post payment fraud detection
software; routine anti-fraud data mining; investigative anti-fraud
auditing; select provider/beneficiary education).
• Specific to pharmacy, controls
include comparing reversal rates; excessive partial fill submissions; high
use patients; review of outliers; codes with medication therapy
for high ingredient costs; claims with high average ingredient cost;
review of brand/generic fill rates; top pharmacies per generic code
rate; controlled substance prescription rates; and ability to conduct
on-site audits of pharmacies who meet these indicators and ability
to review/perform on-site of top one percent of providers who meet
these indicators.